Gosset Ownership
Private
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Wayfinder Biosciences General Information
Developing RNA-targeting small molecules that prevent the production of disease-causing proteins by binding to their mRNA
Contact Information
Primary Industry
Biotech
Corporate Office
San Francisco, California
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Undisclosed collaboration for neurodegeneration program
Wayfinder Biosciences Funding
No funding data available
To view Wayfinder Biosciences's complete valuation and funding history, request access »